CA2500665A1 - Methodes de regulation du poids corporel - Google Patents
Methodes de regulation du poids corporel Download PDFInfo
- Publication number
- CA2500665A1 CA2500665A1 CA002500665A CA2500665A CA2500665A1 CA 2500665 A1 CA2500665 A1 CA 2500665A1 CA 002500665 A CA002500665 A CA 002500665A CA 2500665 A CA2500665 A CA 2500665A CA 2500665 A1 CA2500665 A1 CA 2500665A1
- Authority
- CA
- Canada
- Prior art keywords
- zsig33
- polypeptide
- leu
- antibody
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/63—Motilins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La présente invention concerne une méthode de régulation du poids corporel, de la masse corporelle, du dépôt de graisse et de la glycémie, consistant à mettre le peptide zsig33 en contact avec un anticorps.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41691802P | 2002-10-07 | 2002-10-07 | |
US60/416,918 | 2002-10-07 | ||
PCT/US2003/031804 WO2004033645A2 (fr) | 2002-10-07 | 2003-10-06 | Methodes de regulation du poids corporel |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2500665A1 true CA2500665A1 (fr) | 2004-04-22 |
Family
ID=32093925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002500665A Abandoned CA2500665A1 (fr) | 2002-10-07 | 2003-10-06 | Methodes de regulation du poids corporel |
Country Status (6)
Country | Link |
---|---|
US (1) | US20040208866A1 (fr) |
EP (1) | EP1556084A4 (fr) |
JP (1) | JP2006502227A (fr) |
AU (1) | AU2003282755A1 (fr) |
CA (1) | CA2500665A1 (fr) |
WO (1) | WO2004033645A2 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2300686T3 (es) * | 2003-10-16 | 2008-06-16 | F. Hoffmann-La Roche Ag | Peptidos sw grelina marcados fluorescentemente. |
ES2391853T3 (es) * | 2004-05-04 | 2012-11-30 | Metabolic Pharmaceuticals Ltd. | Métodos para prevenir o tratar trastornos óseos |
JP5649825B2 (ja) | 2007-01-31 | 2015-01-07 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 安定化させたp53ペプチドおよびその使用法 |
KR101525754B1 (ko) | 2007-03-28 | 2015-06-09 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
CN108570097A (zh) | 2010-08-13 | 2018-09-25 | 爱勒让治疗公司 | 拟肽大环化合物 |
MX358886B (es) | 2011-10-18 | 2018-08-31 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos. |
US8987414B2 (en) | 2012-02-15 | 2015-03-24 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
SG11201404648PA (en) | 2012-02-15 | 2014-09-26 | Aileron Therapeutics Inc | Peptidomimetic macrocycles |
EP2914256B1 (fr) | 2012-11-01 | 2019-07-31 | Aileron Therapeutics, Inc. | Acides aminés disubstitués et procédés de préparation et d'utilisation de ceux-ci |
JP2017533889A (ja) | 2014-09-24 | 2017-11-16 | エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. | ペプチド模倣大環状分子およびその使用 |
EP3294318A4 (fr) | 2015-03-20 | 2019-04-03 | Aileron Therapeutics, Inc. | Macrocycles peptidomimétiques et leurs utilisations |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6291653B1 (en) * | 1997-03-24 | 2001-09-18 | Zymogenetics, Inc. | Antibodies to motilin homologs |
EP1232175B1 (fr) * | 1999-11-22 | 2009-07-08 | ZymoGenetics, Inc. | Procede de formation d'un complexe peptide-recepteur a l'aide de polypeptides zsig33. |
-
2003
- 2003-10-06 US US10/679,813 patent/US20040208866A1/en not_active Abandoned
- 2003-10-06 WO PCT/US2003/031804 patent/WO2004033645A2/fr not_active Application Discontinuation
- 2003-10-06 EP EP03774639A patent/EP1556084A4/fr not_active Withdrawn
- 2003-10-06 AU AU2003282755A patent/AU2003282755A1/en not_active Abandoned
- 2003-10-06 JP JP2004543491A patent/JP2006502227A/ja active Pending
- 2003-10-06 CA CA002500665A patent/CA2500665A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2003282755A8 (en) | 2004-05-04 |
WO2004033645A3 (fr) | 2004-08-05 |
EP1556084A2 (fr) | 2005-07-27 |
US20040208866A1 (en) | 2004-10-21 |
EP1556084A4 (fr) | 2006-01-11 |
AU2003282755A1 (en) | 2004-05-04 |
WO2004033645A2 (fr) | 2004-04-22 |
JP2006502227A (ja) | 2006-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8124356B2 (en) | Methods of purifying zsig33 | |
US7655447B2 (en) | ZSIG33-like polynucleotides | |
US7977309B2 (en) | Methods of using motilin homologs | |
US20050208626A1 (en) | SGIP peptides | |
US20080194484A1 (en) | TML polynucleotides | |
CA2500665A1 (fr) | Methodes de regulation du poids corporel | |
CA2289118A1 (fr) | Nouveaux antigenes tumoraux | |
EP1190059A1 (fr) | Peptides sgip | |
EP1278852B1 (fr) | Peptides de type zsig33 | |
JP2002504332A (ja) | 結合組織成長因子ホモローグ | |
US20050250184A1 (en) | Peptide hormones zalpha48 and zsig97 | |
US20030083478A1 (en) | Prostate, testis and uterine polypeptide zpep14 | |
CA2362196A1 (fr) | Polypeptide zpep14 de la prostate, des testicules et de l'uterus | |
ZA200106434B (en) | Prostate, testus and uterine polypeptide zpep14. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |